

8. Brazis PW, Masdeu JC, Biller J. Localization in clinical neurology. 6.a ed. Lippincott Williams & Wilkins; 2011. p. 173–278.
9. Idiáquez CJ, Idiáquez RJF, Benarroch E. Evaluación clínica de las disautonomías. *Rev Chil Neuropsiquiatr.* 2020;58:324–36.
10. Schiemer A. Benign episodic unilateral mydriasis in a flight nurse. *Aerosp Med Hum Perform.* 2017;88:500–2.
11. García-Martín AM, Molina-Martínez FJ, Amer-Ferrer G, Sureda-Ramis B, Moreno-Rojas AJ, Barceló-Artigues I. Unilateral mydriasis during temporal lobe seizures, 10. *Epileptic Disorders;* 2008. p. 165–9.
12. Antonaci F, Sances G, Loi M, Sandrini G, Dumitrache C, Cuzconi M. SUNCT syndrome with paroxysmal mydriasis: clinical and pupillometric findings. *Cephalalgia.* 2010;30:987–90.
13. Li C, Huang X, Tan X, Fang Y, Yan J. A clinical retrospective study of recurrent painful ophthalmoplegic neuropathy in adults. *J Ophthalmol.* 2021;2021:1–5.
14. Martín-Santana I, González-Hernández A, Tandón-Cárdenes L, López-Méndez P. Midriasis benigna episódica. Experiencia en una consulta monográfica de neuro-oftalmología de un hospital terciario. *Neurología.* 2015;30:290–4.
15. Maggioni F, Mainardi F, Malvindi ML, Zanchin G. The borderland of migraine with aura: episodic unilateral mydriasis. *J Headache Pain.* 2011;12:105–7.
16. Edelson RN, Levy DE. Transient benign unilateral pupillary dilation in young adults. *Arch Neurol.* 1974;31:12.

Valeria Valencia-Cifuentes^{a,b,*}, Jairo A. Quiñones^{a,b}

^a *Departamento de Neurología, Fundación Valle del Lili, Cali, Colombia*

^b *Universidad Icesi, Cali, Colombia*

Corresponding author.

E-mail address: Valeriavc1209@gmail.com

(V. Valencia-Cifuentes).

<https://doi.org/10.1016/j.nrleng.2024.01.009>

2173-5808/ © 2024 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Osmotic demyelination syndrome amidst COVID-19: A case report with literature review



Síndrome de desmielinización osmótica en medio de COVID-19

Dear Editor,

Osmotic demyelination syndrome (ODS) is of the most feared rare brain complications that could lead to protracted neurological consequences or death. Its occurrence is strongly associated with rapid correction of chronic hyponatremia.

Hyponatremia is common in COVID-19 patients and is associated with poor prognosis.¹ However, few publications have described ODS in COVID-19 patients. As of May 2023, we found 12 papers in English, five case reports and seven retrospective studies, containing a total of 16 COVID-19 patients with certain ($n=14$) or presumable ($n=2$) ODS^{2–13} (Table 1).

Surprisingly, none of the case reports contain information about the 24-h change in serum sodium, which is of utmost importance in current guidelines.¹⁴

Herein, we present the case of a 44-year-old male, who was admitted to our intensive care unit (ICU) with altered consciousness, positive for COVID-19. His complaints started two weeks prior when he felt nauseous, vomited several times daily, had fever and cough. On day 10 of symptom onset, the patient experienced a single tonic–clonic seizure with loss of consciousness for the first time. The nationwide shortage of hospital beds due to the pandemic has restricted his immediate hospitalization. Subsequent blood tests at a laboratory revealed severe hyponatremia of 112 mmol/L.

On admission (three days later), repeated blood tests revealed hyponatremia of 122 mmol/L, or +10 mmol/L,

indicating that the patient had experienced sodium auto-correction, where the exact correction rate is unknown.

Notable features in the patient's medical history exist. He had managed hypertension with a thiazide diuretic. Thiazide diuretics are a well-known cause of hyponatremia. He also maintained a restrictive diet for a year. In addition, he lost appetite and had been eating less for a week. Finally, he had multiple episodes of vomiting prior to hospital admission. The loss of gastrointestinal fluid results in the release of antidiuretic hormone (ADH), which could cause hyponatremia.

The patient became comatose, and required intubation in early hospitalization days, which made adequate neurologic examination difficult, and magnetic resonance imaging (MRI) impossible. Initial and repeated CT scans of the brain on day 4 were normal. On day 13, his general condition allowed for better examination. Quadriplegia, extraocular muscle palsy, and bulbar syndrome were observed. We performed MRI of the head, which confirmed the diagnosis of ODS (Fig. 1).

Diagnosing ODS is difficult in ICU where encephalopathies are common, including during the COVID-19 era.³ The gold standard is using MRI. However, the need for intensive care limits its feasibility. CT of the brain, while being more accessible and performed under these circumstances, is not sufficiently sensitive.

The question arises whether ODS is underdiagnosed and underreported in COVID-19 patients. Existing studies on COVID-19 patients indicate that ODS may not be rare, particularly in severely ill. In a study by Chougar et al., among 35 COVID-19 patients hospitalized in the ICU with neurological symptoms, three (8.6%) were identified with ODS.⁴ Fitsiori et al. found one ODS case among nine ICU patients (11.1%),⁵ Neumann et al. identified one case among 30 COVID-19 patients (3.3%), with the patient being in a critical condition,⁶ and Jensen-Kondering et al. reported one case of ODS in 12 patients (8.3%), with the patient being severely

Table 1 Review of publications about COVID-19 and osmotic demyelination syndrome as of May 2023.

First author	Type of study	Patients with ODS	Initial sodium levels (mmol/L)	Maximum sodium correction (mmol/L)	Known risk factors for ODS ^a	Neurological symptoms	Additional important details	Outcomes
Chougar et al. 2020 ²	Retrospective MRI	3 (<i>n</i> = 73)	N/A	N/A	N/A	N/A	N/A	N/A
Fitsiori et al. 2020 ³	Retrospective MRI	1 (<i>n</i> = 9)	N/A	N/A	Hypertension, diabetes	Confusion	N/A	N/A
Neumann et al. 2020 ⁴	Retrospective	1 (<i>n</i> = 30)	N/A	N/A	N/A	Gait disturbance, altered mental state, dysarthria	N/A	N/A
Saleh et al. 2020 ⁵	Case report	1	103	+11 ^b	Urinary retention, SIADH, hypokalemia, hyponatremia hypertension	Confusion, disorientation, anosmia, dysgeusia	N/A	Improvement
Chang et al. 2020 ^{c,6}	Case report	1	Normal	N/A	Hypertension	Coma, bilateral ophthalmoplegia, quadriplegia	Presumable, not confirmed diagnosis.	Improvement
Lambrecq et al. 2021 ⁷	Retrospective MRI/EEG	3 (<i>n</i> = 57)	N/A	N/A	N/A	N/A	N/A	N/A
Rehman et al. 2021 ⁸	Case report	1	123	+38 (for 48–72 h)	Hyponatremia, diabetes, hypertension	Disorientation, gait disturbance, disorganized speech	The lowest level of measured sodium was 88 mmol/L.	Improvement

Table 1 (Continued)

First author	Type of study	Patients with ODS	Initial sodium levels (mmol/L)	Maximum sodium correction (mmol/L)	Known risk factors for ODS ^a	Neurological symptoms	Additional important details	Outcomes
Jensen-Kondering et al. 2021 ^{c,9}	Retrospective imaging	1 (n = 12)	N/A	N/A	N/A	N/A	Presumable, not confirmed diagnosis. Not hyponatremic.	N/A
Ser et al. 2021 ¹⁰	Retrospective MRI	1 (n = 26)	N/A	N/A	N/A	New-onset encephalopathy Quadriplegia	N/A	N/A
Elizondo et al. 2021 ¹¹	Retrospective MRI	1 (n = 47)	N/A	N/A	N/A	Quadriplegia	N/A	N/A
Ghosh et al. 2022 ¹²	Case report	1	136	+6 ^b	Diabetes, in a hyperglycemic state	Akinetic mutism, Parkinsonism	Non-dyselectrolytemic ODS. Closely monitored serum sodium, according to authors.	Improvement
Ivanova et al. 2023 ¹³	Case report	1	130	+17 (for 48 h)	Hyponatremia	Bulbar syndrome, quadriplegia, resting tremor	The lowest level of measured sodium was 116 mmol/L.	Survived but no improvement.

ODS = osmotic demyelination syndrome, MRI = magnetic resonance imaging, N/A = not available, SIADH = Syndrome of Inappropriate Antidiuretic Hormone Secretion, EEG = electroencephalogram.

^a Risk factors that may secondarily lead to ODS are also included.

^b Unknown period of correction.

^c Unconfirmed but presumable ODS according to the authors' description or imaging findings.




Figure 1 Axial fluid-attenuated inversion recovery magnetic resonance imaging (FLAIR MRI) demonstrating a centrally located area of increased signal in the pons (A) and a moderately homogeneous signal enhancement bilaterally symmetrical in the basal ganglia with symmetrical foci of enhancement in the posterior thalami (B), typical for pontine (A) and extrapontine (B) myelinolysis or osmotic demyelination syndrome.

ill.¹¹ However, these studies suffer from small sample sizes, and conclusions would be premature.

Our patient had stable sodium levels during the hospital stay before establishing diagnosis. The maximum measured increase in serum sodium over 24 h (+8 mmol/L) was within the current recommended therapeutic limits. Multiple cases in literature have also reported ODS, despite adherence to guidelines. Tandukar et al. highlight 19 publications encompassing 21 patients, 19 of whom (90.5%) had risk factors for ODS.¹⁵

However, MacMillan et al. recently showed that ODS can develop in the absence of rapid sodium correction, and an accompanying editorial by Ayus and Moritz questioned current guidelines. This is a large study including 22,858 patients, 3632 of whom (17.7%) had rapid correction of hyponatremia, defined as > 8 mmol/L/24 h. ODS appeared to be a rare condition, developing in only 12 (0.05%) patients. Most notably, seven (58%) of the 12 patients were not rapidly corrected.^{16,17} Yet, they might have undergone uncontrolled sodium correction. As illustrated by our case report, auto-correction may occur at any time and sodium levels may change dramatically, particularly outside the hospital setting. Also, serum sodium levels of patients are unknown prior to first measurement. These limitations apply in general.

Thus, we posit that undocumented correction of hyponatremia could significantly contribute to the uncertainty regarding established therapeutic guidelines. Further research is needed to explore its role.

Ethical standards

This research was conducted in accordance with the principles of the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from the relative in accordance with the Declaration of Helsinki.

Consent to publish

The relative has consented to submitting the case report to the journal.

Availability of data and materials

The authors take full responsibility for the data, analysis, and interpretation of the research, and have full access to all data.

Funding

This work is supported by the Bulgarian Ministry of Education and Science under National Program “Young Scientists and Postdoctoral Students – 2”.

Conflict of interests

The authors declare that they have no conflict of interest.

References

1. Purja S, Oh S, Kim E. A systematic review on neurological aspects of COVID-19: exploring the relationship between COVID-19-related olfactory dysfunction and neuroinvasion. *Front Neurol.* 2022;13, <http://dx.doi.org/10.3389/fneur.2022.887164>.
2. Chougar L, Shor N, Weiss N, Galanaud D, Leclercq D, Mathon B, et al. Retrospective observational study of brain MRI findings in patients with acute SARS-CoV-2 infection and neurologic manifestations. *Radiology.* 2020;297:E313–23, <http://dx.doi.org/10.1148/radiol.2020202422>.
3. Fitsiori A, Pugin D, Thieffry C, Lalive P, Vargas MI. COVID-19 is associated with an unusual pattern of brain microbleeds in critically ill patients. *J Neuroimaging.* 2020;30:593–7, <http://dx.doi.org/10.1111/jon.12755>.
4. Neumann B, Schmidbauer ML, Dimitriadis K, Otto S, Knier B, Niesen W-D, et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. *J Neurol Sci.* 2020;418:117090, <http://dx.doi.org/10.1016/j.jns.2020.117090>.
5. Saleh AO, Al-Shokri SD, Ahmed A, Musa AE, Mohamed MFH. Urinary retention and severe hyponatremia: an unusual presentation of COVID-19. *Eur J Case Rep Intern Med.* 2020, <http://dx.doi.org/10.12890/2020.001905>.
6. Chang P, Tasch ES, Rapoport LN, Bakhadirov K. A post-infectious steroid-responsive brainstem lesion associated with COVID-19. *Neurohospitalist.* 2020;11:152–5, <http://dx.doi.org/10.1177/1941874420959544>.
7. Lambrecq V, Hanin A, Munoz-Musat E, Chougar L, Gassama S, Delorme C, et al. Association of clinical biological, and brain magnetic resonance imaging findings with electroencephalographic findings for patients with COVID-19. *JAMA Netw Open.* 2021;4:e211489, <http://dx.doi.org/10.1001/jamanetworkopen.2021.1489>.
8. Abd Ur Rehman M, Abdulrahman AF, Zainab A, Paksoy Y, Kharma N. Hyponatremia and extrapontine myelinolysis in a patient with COVID-19: a case report. *Clin Case Rep.* 2021;9, <http://dx.doi.org/10.1002/ccr3.4463>.

9. Jensen-Kondering U, Neumann A, Margraf NG, Gövert F, Brügge-
mann N, Schunk D, et al. Cerebral imaging in patients with
COVID-19 and neurological symptoms: first experience from two
University Hospitals in Northern Germany. *RöFo – Fortschritte
Auf Dem Gebiet Der Röntgenstrahlen Und Der Bildgebenden Ver-
fahren*. 2020, <http://dx.doi.org/10.1055/a-1265-7209>.
10. Ser MH, Tanriverdi U, Özkara Ç, Saip S, Aliş C, Güleç ZEK,
et al. Analysis of neurology consultations in hospitalized
patients with COVID-19. *Acta Neurol Belg*. 2022;122:1011–8,
<http://dx.doi.org/10.1007/s13760-021-01836-6>.
11. Mendez Elizondo EF, Valdez Ramírez JA, Barraza Aguirre
G, Dautt Medina PM, Berlanga Estens J. Central ner-
vous system injury in patients with severe acute respira-
tory syndrome coronavirus 2: MRI findings. *Cureus*. 2021,
<http://dx.doi.org/10.7759/cureus.18052>.
12. Ghosh R, Ray A, Roy D, Das S, Dubey S, Benito-León
J. Parkinsonism with akinetic mutism following osmotic
demyelination syndrome in a SARS-CoV-2 infected elderly
diabetic woman: a case report. *Neurología*. 2022;37:706–8,
<http://dx.doi.org/10.1016/j.nrl.2021.09.007>.
13. Ivanova NI, Tsalta-Mladenov ME, Georgieva DK, Andonova
SP. Central pontine myelinolysis as a late complication
after hyponatremia and COVID-19 infection. *Cureus*. 2023,
<http://dx.doi.org/10.7759/cureus.35191>.
14. Hoorn EJ, Zietse R. Diagnosis and treatment of hypona-
tremia: compilation of the guidelines. *J Am Soc Nephrol*.
2017;28:1340–9, <http://dx.doi.org/10.1681/asn.2016101139>.
15. Tandukar S, Sterns RH, Rondon-Berrios H. Osmotic demyeli-
nation syndrome following correction of hyponatremia
by ≤ 10 mEq/L per day. *Kidney360*. 2021;2:1415–23,
<http://dx.doi.org/10.34067/kid.0004402021>.
16. MacMillan TE, Shin S, Topf J, Kwan JL, Wainerman A, Tang
T, et al. Osmotic demyelination syndrome in patients
hospitalized with hyponatremia. *NEJM Evid*. 2023;2,
<http://dx.doi.org/10.1056/evidoa2200215>.
17. Ayus JC, Moritz ML. Hyponatremia treatment guidelines—
have they gone too far? *NEJM Evid*. 2023;2,
<http://dx.doi.org/10.1056/evide2300014>.
- G. Dimitrov^{a,*}, D. Naeva^{a,1}, R. Duparinoa^{a,1},
S. Stratieva^{a,1}, V. Manev^{b,1}, K. Prinova^{a,1}
- ^a *Clinic of Neural Diseases, Military Medical Academy, Sofia, Bulgaria*
^b *Fakultät für Mathematik und Informatik, Ruprecht Karl University of Heidelberg, Germany*
- * Corresponding author.
E-mail address: dr.gabrielidimitrov@gmail.com
(G. Dimitrov).
- ¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.nrl.2023.11.001>
0213-4853/ © 2024 Sociedad Española de Neurología. Published by
Elsevier España, S.L.U. This is an open access article under the CC
BY license (<http://creativecommons.org/licenses/by/4.0/>).